129765-95-3

Basic information

• Product Name: 3-TERT-BUTOXYCARBONYLAMINO-3-METHYL-BUTYRIC ACID
• Synonyms: 3-TERT-BUTOXYCARBONYLAMINO-3-METHYL-BUTYRIC ACID;N-Boc-3-amino-3-methylbutanoic Acid;3-(tert-butoxycarbonylamino)-3-methylbutanoic acid;3-(tert-butoxycarbonyl)-3-Methylbutanoic acid;Butanoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-3-methyl-;3-[[(1,1-Dimethylethoxy)carbonyl]amino]-3-methylbutanoic acid
• CAS NO: 129765-95-3
• Molecular Formula: C₁₀H₁₉NO₄
• Molecular Weight: 217.26216
• Mol File: 129765-95-3.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 346.5±25.0 °C(Predicted)
• Appearance: /
• Density: 1.082±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 4.45±0.10(Predicted)
• CAS DataBase Reference: 3-TERT-BUTOXYCARBONYLAMINO-3-METHYL-BUTYRIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-TERT-BUTOXYCARBONYLAMINO-3-METHYL-BUTYRIC ACID(129765-95-3)
• EPA Substance Registry System: 3-TERT-BUTOXYCARBONYLAMINO-3-METHYL-BUTYRIC ACID(129765-95-3)

Safety Data

• Hazardous Substances Data: 129765-95-3(Hazardous Substances Data)

Usage

Chemical Properties

White powder

Uses

3-((tert-Butoxycarbonyl)amino)-3-methylbutanoic Acid is an intermediate used in the synthesis of (2E)-5-(tert-Butyloxycarbonylamino)-5-methylhex-2-enoic Acid (B809765), which is used in the preparation of C-terminal sulfonamide analogs of NN703 as growth hormone secretagogues.

Upstream product

• 625-05-8 3-amino-3-methylbutanoic acid 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 130985-44-3 N-α--L-phenylalanyl>-N^α-methyl-N^im-tosyl-L-histydyl>-5(S)-amino-6-cyclohexyl-4(S)-hydroxy-2(S)-isopropylhexanoyl>-L-isoleucyl>-2-pyridylmethylamine 
• 136630-98-3 (2-{(S)-1-[2-((1S,2S)-3-{(1S,2S)-1-[(4-Amino-2-methyl-pyrimidin-5-ylmethyl)-carbamoyl]-2-methyl-butylcarbamoyl}-1-cyclohexylmethyl-2-hydroxy-propylcarbamoyl)-ethylcarbamoyl]-2-phenyl-ethylcarbamoyl}-1,1-dimethyl-ethyl)-carbamic acid tert-butyl ester 
• 185526-02-7 C₃₃H₄₅N₃O₅ 
• 167216-22-0 tert-butyl (3-hydroxy-1,1-dimethyl-propyl)-carbamate 
• 168057-04-3 3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-2-[[2'-[[[(methylamino)carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-3-oxo-1H-2-benzazepin-4(R)-yl]butanamide, trifluoroacetate 
• 885693-30-1 [3-(4-{4-[(4-cyano-1H-imidazole-2-carbonyl)amino]-3-cyclohex-1-enylphenyl}piperidin-1-yl)-1,1-dimethyl-3-oxopropyl]carbamic acid tert-butyl ester 
• 130985-46-5 N-α--L-phenylalanyl>-N^α-methyl-L-histidyl>-5(S)-amino-6-cyclohexyl-4(S)-hydroxy-2(S)-isopropylhexanoyl>-L-isoleucyl>(1-oxo-2-pyridyl)methylamine 
• 130985-45-4 N-α--L-phenylalanyl>-N^α-methyl-L-histydyl>-5(S)-amino-6-cyclohexyl-4(S)-hydroxy-2(S)-isopropylhexanoyl>-L-isoleucyl>-2-pyridylmethylamine 
• 135378-87-9 [2-((S)-1-{[(S)-1-[(1S,2S,4S)-1-Cyclohexylmethyl-2-hydroxy-5-methyl-4-((S)-2-methyl-butylcarbamoyl)-hexylcarbamoyl]-2-(1H-imidazol-4-yl)-ethyl]-methyl-carbamoyl}-2-phenyl-ethylcarbamoyl)-1,1-dimethyl-ethyl]-carbamic acid tert-butyl ester 
• 135378-56-2 (2S,4S,5S)-5-[(S)-2-{[(S)-2-(3-Amino-3-methyl-butyrylamino)-3-phenyl-propionyl]-methyl-amino}-3-(1H-imidazol-4-yl)-propionylamino]-6-cyclohexyl-4-hydroxy-2-isopropyl-hexanoic acid ((S)-2-methyl-butyl)-amide 
• 130985-58-9 N-α-(β-L-valyl)-L-phenylalanyl-N^α-methyl-L-histidyl>-5(S)-amino-6-cyclohexyl-4(S)-hydroxy-2(S)-isopropylhexanoyl>-L-isoleucyl>(1-oxo-2-pyridyl)methylamine tris(trifluoroacetate) 
• 130985-57-8 N-α-(β-L-valyl-L-phenylalanyl)-N^α-methyl-L-histydyl>-5(S)-amino-6-cyclohexyl-4(S)-hydroxy-2(S)-isopropylhexanoyl>-L-isoleucyl>-2-pyridylmethylamine tris(trifluoroacetate) 
• 136630-77-8 (3-amino-3-methylbutyryl)-Phe-β-Ala-ACHPA-Ile N-<(4-amino-2-methyl-5-pyrimidinyl)methyl>amide dihydrochloride 
• 145455-23-8 L-158432 

Relevant articles and documents

NOVEL FERROPORTIN INHIBITORS

The invention relates to novel ferroportin inhibitors of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.

3-Amino-N-adamantyl-3-methylbutanamide derivatives as 11β- hydroxysteroid dehydrogenase 1 inhibitor

Many adamantane derivatives have been demonstrated to function as 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors. 3-Amino-N-adamantyl-3-methylbutanamide derivatives were optimized by structure-based drug design. Compound 8j exhibited a good in vitro and ex vivo inhibitory activity against both human and mouse 11β-HSD1.

NOVEL PYRIDINE DERIVATIVES

The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.